Document is current
Any future updates will be listed below
-
Authors
Xiong, Xiwen http://orcid.org/0000-0001-5802-4994
Yang, Chenyan
He, Wei-Qi http://orcid.org/0000-0003-3137-8420
Yu, Jiahui
Xin, Yue
Zhang, Xinge
Huang, Rong
Ma, Honghui
Xu, Shaofang
Li, Zun
Ma, Jie
Xu, Lin
Wang, Qunyi
Ren, Kaiqun
Wu, Xiaoli S.
Vakoc, Christopher R. http://orcid.org/0000-0002-1158-7180
Zhong, Jiateng
Zhong, Genshen http://orcid.org/0000-0003-2086-3834
Zhu, Xiaofei
Song, Yu
Ruan, Hai-Bin http://orcid.org/0000-0002-3858-1272
Wang, Qingzhi
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 19 August 2022
First Online: 3 September 2022
Competing interests
: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences, and C4 Therapeutics; has served on the scientific advisory board of KSQ Therapeutics, Syros Pharmaceuticals, and Treeline Biosciences; has received research funding from Boehringer-Ingelheim and Treeline Biosciences; and has a stock option from Treeline Biosciences. All other authors declare no competing interests.
